Literature DB >> 17387559

Surgical treatment for hepatocellular carcinoma detected after successful interferon therapy.

Shoji Kubo1, Hiromu Tanaka, Shigekazu Takemura, Satoshi Yamamoto, Seikan Hai, Tsuyoshi Ichikawa, Shintaro Kodai, Hiroji Shinkawa, Taichi Shuto, Kazuhiro Hirohashi.   

Abstract

PURPOSE: Interferon therapy suppresses the development of hepatocellular carcinoma (HCC) and tumor recurrence after a resection of HCC in patients with chronic hepatitis C. However, the value of a liver resection and which method is best for the treatment of HCC detected after successful interferon therapy remains to be clarified. The risk factors for tumor recurrence after a liver resection for HCC detected after successful interferon therapy were investigated to determine the appropriate operative method for such HCC.
METHODS: Risk factors including the clinicopathologic findings and the operative methods for tumor recurrence were evaluated by univariate and multivariate analyses in 24 patients who underwent liver resection for HCC detected after successful interferon therapy (sustained viral response or biochemical response).
RESULTS: According to a univariate analysis, large tumor (> 2 cm, P = 0.0326), multiple tumors (P = 0.0372), nonanatomic resection (P = 0.0103), and positive surgical margin (< 5 mm of a free surgical margin, P = 0.0245) were possible risk factors for short tumor-free survival time after surgery. A multivariate analysis showed that large tumor (P = 0.0407), nonanatomic resection (P = 0.0215), and positive surgical margin (P = 0.0253) were independent risk factors for a short tumor-free survival time after surgery.
CONCLUSION: An anatomic resection with an appropriate surgical margin (> or = 5 mm of a free surgical margin) is recommended for patients with HCC detected after successful interferon therapy.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17387559     DOI: 10.1007/s00595-006-3403-6

Source DB:  PubMed          Journal:  Surg Today        ISSN: 0941-1291            Impact factor:   2.549


  29 in total

1.  Primary carcinoma of the liver: a study of 100 cases among 48,900 necropsies.

Authors:  H A EDMONDSON; P E STEINER
Journal:  Cancer       Date:  1954-05       Impact factor: 6.860

2.  Relationship between response to previous interferon therapy and postoperative recurrence of hepatitis C virus-related hepatocellular carcinoma.

Authors:  Takahiro Uenishi; Shoji Kubo; Kazuhiro Hirohashi; Hiromu Tanaka; Taichi Shuto; Takatsugu Yamamoto; Akihiro Tamori; Seikan Hai; Hiroaki Kinoshita; Shuhei Nishiguchi
Journal:  Hepatol Res       Date:  2002-12       Impact factor: 4.288

3.  Patterns of and risk factors for recurrence after liver resection for well-differentiated hepatocellular carcinoma: a special reference to multicentric carcinogenesis after operation.

Authors:  S Kubo; H Kinoshita; K Hirohashi; H Tanaka; T Tsukamoto; H Hamba; T Shuto; T Yamamoto; T Ikebe; K Wakasa
Journal:  Hepatogastroenterology       Date:  1999 Nov-Dec

4.  Risk factors for recurrence after resection of hepatitis C virus-related hepatocellular carcinoma.

Authors:  S Kubo; K Hirohashi; H Tanaka; T Tsukamoto; T Shuto; T Ikebe; T Yamamoto; K Wakasa; S Nishiguchi; T Kuroki; H Kinoshita
Journal:  World J Surg       Date:  2000-12       Impact factor: 3.352

5.  Clinical significance of hepatic resection in hepatocellular carcinoma: analysis by disease-free survival curves.

Authors:  M Sakon; K Umeshita; H Nagano; H Eguchi; S Kishimoto; A Miyamoto; S Ohshima; K Dono; S Nakamori; M Gotoh; M Monden
Journal:  Arch Surg       Date:  2000-12

6.  Effect of interferon-alpha on progression of cirrhosis to hepatocellular carcinoma: a retrospective cohort study. International Interferon-alpha Hepatocellular Carcinoma Study Group.

Authors: 
Journal:  Lancet       Date:  1998-05-23       Impact factor: 79.321

7.  Interferon therapy after tumor ablation improves prognosis in patients with hepatocellular carcinoma associated with hepatitis C virus.

Authors:  Yasushi Shiratori; Shuichiro Shiina; Takuma Teratani; Masatoshi Imamura; Shun'taro Obi; Shin'pei Sato; Yukihiro Koike; Haruhiko Yoshida; Masao Omata
Journal:  Ann Intern Med       Date:  2003-02-18       Impact factor: 25.391

8.  Relationship between the recurrence of hepatocellular carcinoma (HCC) and serum alanine aminotransferase levels in hepatectomized patients with hepatitis C virus-associated cirrhosis and HCC.

Authors:  K Tarao; S Takemiya; S Tamai; Y Sugimasa; S Ohkawa; M Akaike; H Tanabe; A Shimizu; M Yoshida; A Kakita
Journal:  Cancer       Date:  1997-02-15       Impact factor: 6.860

9.  Relation of interferon therapy and hepatocellular carcinoma in patients with chronic hepatitis C. Osaka Hepatocellular Carcinoma Prevention Study Group.

Authors:  Y Imai; S Kawata; S Tamura; I Yabuuchi; S Noda; M Inada; Y Maeda; Y Shirai; T Fukuzaki; I Kaji; H Ishikawa; Y Matsuda; M Nishikawa; K Seki; Y Matsuzawa
Journal:  Ann Intern Med       Date:  1998-07-15       Impact factor: 25.391

10.  Relationship between multicentric occurrence of hepatocellular carcinoma and histology of noncancerous hepatic tissue in patients with chronic hepatitis C.

Authors:  S Kubo; T Yamamoto; T Ikebe; T Shuto; K Hirohashi; H Tanaka; T Tsukamoto; K Wakasa; H Kinoshita
Journal:  Jpn J Cancer Res       Date:  1999-10
View more
  9 in total

Review 1.  Survival after anatomic resection versus nonanatomic resection for hepatocellular carcinoma: a meta-analysis.

Authors:  Jinggui Chen; Kai Huang; Jianghong Wu; Huiyan Zhu; Yingqiang Shi; Yanong Wang; Guangfa Zhao
Journal:  Dig Dis Sci       Date:  2010-11-17       Impact factor: 3.199

2.  Prevention of cancer recurrence after treatment for hepatitis C virus-related hepatocellular carcinoma by interferon therapy.

Authors:  Shoji Kubo
Journal:  Clin J Gastroenterol       Date:  2009-04-08

Review 3.  Reappraisal of evidence of microscopic portal vein involvement by hepatocellular carcinoma cells with stratification of tumor size.

Authors:  Yuesi Zhong; Meihai Deng; Ruiyun Xu
Journal:  World J Surg       Date:  2015-05       Impact factor: 3.352

4.  Long-term surviving patient with inferior vena cava tumor thrombus and extrahepatic metastasis after spontaneous ruptured hepatocellular carcinoma.

Authors:  Kensaku Sanefuji; Kengo Fukuzawa; Masahiro Okamoto; Seiichiro Kai; Hajime Takaki; Yonemasu Hirotoshi; Akira Motohiro; Kenzo Wakasugi
Journal:  Clin J Gastroenterol       Date:  2011-02-15

5.  High dorsal resection for recurrent hepatocellular carcinoma originating in the caudate lobe.

Authors:  Tohru Utsunomiya; Masahiro Okamoto; Eiji Tsujita; Mitsuhiko Ohta; Tetsuzo Tagawa; Ayumi Matsuyama; Jin Okazaki; Manabu Yamamoto; Shinichi Tsutsui; Teruyoshi Ishida
Journal:  Surg Today       Date:  2009-09-24       Impact factor: 2.549

Review 6.  Surgical treatment of hepatocellular carcinoma.

Authors:  Kiyoshi Hasegawa; Norihiro Kokudo
Journal:  Surg Today       Date:  2009-09-27       Impact factor: 2.549

7.  Second hepatic resection for recurrent hepatocellular carcinoma in patients with chronic hepatitis C.

Authors:  Shoji Kubo; Shigekazu Takemura; Takahiro Uenishi; Takatsugu Yamamoto; Kazuki Ohba; Masao Ogawa; Seikan Hai; Tsuyoshi Ichikawa; Shintaro Kodai; Hiroji Shinkawa; Hiromu Tanaka
Journal:  World J Surg       Date:  2008-04       Impact factor: 3.352

8.  Prognostic impact of treatment modalities on patients with single nodular recurrence of hepatocellular carcinoma.

Authors:  Masaki Ueno; Kazuhisa Uchiyama; Satoru Ozawa; Takayuki Nakase; Naoki Togo; Shinya Hayami; Hiroki Yamaue
Journal:  Surg Today       Date:  2009-07-29       Impact factor: 2.549

9.  Obesity and recurrence-free survival in patients with hepatocellular carcinoma after achieving sustained virological response to interferon therapy for chronic hepatitis C.

Authors:  Hiroji Shinkawa; Shogo Tanaka; Shigekazu Takemura; Tokuji Ito; Takanori Aota; Masaki Koda; Toru Miyazaki; Takatsugu Yamamoto; Shoji Kubo
Journal:  Ann Gastroenterol Surg       Date:  2018-06-22
  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.